Nanoformulation and antibiotic releasing property of cefotaxime nanoparticles by Al-Moahmmedawi, Maysaa Chasib
 
Vol. 15(14), pp. 539-548, 6 April, 2016 
DOI: 10.5897/AJB2015.14980 
Article Number: 95C8D3F57894 
ISSN 1684-5315 
Copyright © 2016 
Author(s) retain the copyright of this article 
http://www.academicjournals.org/AJB 






Full Length Research Paper 
 
Nanoformulation and antibiotic releasing property of 
cefotaxime nanoparticles 
 
Maysaa Chasib Al-Moahmmedawi 
 
Scholar Rescue Fund- Institute of International Education (IIE) USA.  
 
Received 17 September, 2015; Accepted 10 March, 2016 
 
The objective of this study was to design nano-antibiotic to enhance their release from biomaterial 
agents. Cefotaxime was used as a model antibiotic substance in this carrier system. These 
nanoparticles were preformulated using different concentrations of polycaprolactone (PCL) and poly 
(vinyl alcohol) as coating material and prepared using double emulsion solvent evaporation method. 
The physiochemical properties of cefotaxime nano-antibiotic (Cefo-NPs) stability were determined. 
Results showed that the encapsulation efficiency of nanoparticles increased with increase in polymer 
concentration. In addition, dynamic light scattering (DLS) and atomic force microscope (AFM) indicated 
that the particles size were in the range of 189 to 219 nm. The drug release profile of Cefo-NPs shows 
rapidly the release behaviour under acidic environment. And thus make it a promising tool for control 
bacterial infection. 
 





Cefotaxime is a water soluble semisynthetic third 
generation of cephalosporin antibiotics, used for serious 
infections caused by susceptible strains of micro-
organisms in lower respiratory infections, genitourinary 
infections, gynaecologic infections, skin infections, and 
central nervous system infections (Morelli, 2003). It acts 
by inhibiting bacterial cell wall synthesis.  
Recent studies focused on using composite 
nanomaterials of silver-chitosan, chitosan-arginine, zinc-
iron oxide, and polymer-antibiotics to control bacterial 
colonization and infection and potentially could be used 
as future therapeutic agents (Huang et al., 2011a, 2011b; 
Lellouche et al., 2012). Although, their mechanism of 
action is still  unclear,  but  each  of  these  materials  has 
unique features that influence certain types of bacteria 
(Sivaraman and Ramamurthi, 2013). Additionally, 
different approaches were used to combine antibacterial 
materials to achieve desirable effects. 
Nanocarriers, such as pH-sensitive nanoparticles, may 
represent one of these approaches that constitute an 
alternative strategy to overcome the difficulties that are 
related to microbial resistance and poor oral 
bioavailability (Ankola et al., 2010). It was found out that 
sustained release formulations prolong the action of the 
drug for a long period of time and also decrease the 
frequency of drug dosage. A sustained release 
formulation reduces the frequent drug administration 
(Shekhar et al., 2010). 
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Table 1. Formulation plan or cefotaxime nanoparticles. 
 
Nanoformulation Cefotaxime (mg/ml) PCL polymer (w/v %) PVA (w/v %) 
Cef-NP-1 5 1 0.2 
Cef-NP-2 5 2 0.2 
Cef-NP-3 5 1 0.3 




Poly ε-caprolactone (PCL) is a synthetic, biodegradable, 
biocompatible polymer often used in the formulation of 
nanoparticles. Nanoparticles prepared using PCL as a 
matrix was found to be larger than that prepared with 
other polymers. The colloidal suspension exhibited 
sustained release profile (Kumari et al., 2010). Since it is 
a low cost material, it is approved by the US Food and 
Drug Administration, and experience’s slow degradation 
in the body (Mora-Huertas et al., 2010; Haddadi et al., 
2008). The aim of this study was to prepare and 
characterize new nanoformulation of cefotaxime with PCL 
using solvent evaporation method. 
 
 
MATERIALS AND METHODS  
 
Preparation of standard curve of cefotaxime 
 
From the stock standard solution, aliquots of 2, 4, 6, 8, and 10 ml 
were pipette out and the volume was made upto 10 ml with 
phosphate buffered saline (PBS) pH 7.4 to obtain concentrations in 
the range of 20 to 100 μg/ml. The absorbance of these solutions 
was measured at 256 nm by UV-Visible spectrophotometer, using 
phosphate buffer of pH 7.4 as blank. The absorbance values were 
plotted against concentration to obtain the standard graph. 
 
 
Formulation of cefotaxime nanoparticles (Cefo-NPs) 
 
Cefotaxime loaded nanoparticles were prepared with water in oil in 
water (w/o/w) double emulsion- solvent evaporation method. In this 
method, cefotaxime equivalent to 5% w/v was dissolved in 500 μl of 
PBS (0.01 M, pH 7.4) to form cefotaxime aqueous solution. The 
cefotaxime aqueous solution was emulsified in an organic phase 
consisting of 1 to 2% of the PCL polymer inorganic solvent di-cholo 
methane (DCM) to form primary water in oil emulsion. The emulsion 
was further emulsified in an aqueous 12.5 ml of poly-vinyl alcohol 
(PVA) stock solution (100 ml 2 to 3% w/v), as shown in Table 1, to 
form w/o/w emulsion. The emulsification was carried out using a 
micro tip probe sonicator (VC 505, Vibracell Sonic, Newton, MA, 
USA) set as 55 W of energy output for 5 min over an ice bath by 
adding the primary emulsion in dropwise to the 20 ml of phosphate 
buffer (0.01 M, pH 7.4). The emulsion was stirred for 18 h on a 
magnetic stir plate at room temperature to allow the evaporation of 
the organic solvent. Further 1 h vacuum drying was also performed 
to remove any residual organic solvent present. Any excess amount 
of PVA was removed by ultracentrifugation at 16000 rpm at 40°C 
for 20 min (Remi, India) followed by washing with double distilled 
water. The supernatant was collected and kept for an estimation of 
the amount of the drug which was not encapsulated. The recovered 
nanoparticulate suspension was lyophilized for two days (-800°C 
and <10 mm mercury pressure, LYPHILOCK 12, Labconco, Kansas 
City, MO, USA) to provide the lyophilized powder for further use 
(Niwa et al., 1994). 
Percentage yield  
 
The percentage practical yield was calculated to know about the 
percent yield or efficiency of any method, which would help in the 
selection of appropriate method of production. Practical yield was 
calculated as the weight of the dry nanoparticles recovered from 
each batch in relation to the sum of the starting material (Ramteke 
et al., 2006). 
 
Percentage yield (PY) = (Practical yield/Theoretical yield) × 100 
 
 
Fourier transform infra-red spectroscopy study 
 
The Fourier transform infrared (Shimadzu-FTIR, Mo-del-8000 
provided by Chemical Department, College of Science, Al-Nahrain 
University, Baghdad, Iraq) analysis was conducted to verify the 
possibility of chemical bonds between drug and polymer. Samples 
of pure cefotaxime, pure PCL and Cefotaxime-PCL physical mixture 
1:1 were scanned in the IR range from 400 to 4000 cm
-1
 with 
carbon black as reference. The detector was purged carefully by 




Encapsulation efficiency (EE %)  
 
The encapsulation efficiency, (EE %), was measured at wavelength 
of 256 nm by UV spectrometer (Spectronic Genesys 10 Bio, 
Thermo Electron Cooperation, WI, USA). The standard curve was 
prepared using drug concentration ranging from 1 to 10 mcg/ml and 
had a regression equation of y = 0.076x with R
2
 = 0.988. In each 
sample, EE% was measured by separating the aqueous phase with 
the colloidal one after centrifuge at 14,000 rpm for 30 min (VWR 
micro 18R, VWR Inc., West Chester, USA). The encapsulation 
efficiency of the drug loading was calculated using the following 
equation (Shabouri, 2003):  
 










 is the total drug amount and A
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The size distributions along the volume mean diameters of the 
suspending particles were measured by dynamic scattering particle 
size analyser (Nanotrac Particle Analyzer 150, Microtrac Inc., PA, 
USA) (Alexis et al., 2008). 
 
 
Determination of drug release profile of Cefo-NPs 
 
One millilitre of the aformentioned Cef-PCL nanoparticles was 
centrifuged for 45 min  at  20,000 rpm.  After  that,  the  precipitated  




Table 2. Practical yield of nanoparticles. 
 
Formulation Practical yield (mg) Total amount of ingredients (mg) Percentage yield (%) 
Cef-NP1 54 84 64.2 
Cef-NP2 48 64 75 
Cef-NP3 45 57 78.9 










Cef-PCL was redispersed in 1 ml of buffer solutions at pH 1.5, 4.5, 
6.8, and 7.2. The dispersed particles were incubated for 1, 2, 4, 6, 
12, 24, 48, 72 and 96 h at 37°C, which was conducted in triplicate. 
The amount of released drug was measured at 256 nm by UV- 
spectrometry. These results were shown as average ± standard 
deviation (n= 3). In addition, the drug loading efficiency (7.2 wt.%) 
was measured in the same manner. Briefly, cefotaxime weight was 
measured after lyophilisation and then dissolved in 1 ml of distilled 
water. The loaded amount of drug was measured by UV-
spectrometry, using the following formula (Alexis et al., 2008): 
 
Drug loading efficiency = (Weight of drug in nanoparticles/Weight of 
PCL-PVA) × 100. 
 
 
RESULTS AND DISCUSSION  
 
The w/o/w multiple emulsion solvent evaporation method 
is the mostly used technique for encapsulation of water-
soluble drug. And  it  was  the  method  of  choice  for  the 
water-soluble cefotaxime drug (Kim et al., 2002). Four 
formulations of Cefo-NPs were formulated using different 
polymer emulsifier ratios, as shown in Table 2. The 
formulations are subjected to evaluation parameters like 
particle size, surface topography, drug encapsulation, 
and zeta potential.  
Physicochemical characteristics, such as particle size 
and surface properties, all represented important 
parameters for determining the in vitro drug release, 
cellular uptake, and cytotoxicity of nanoparticles. The in 
vivo pharmacokinetics and biodistribution, influenced the 
therapeutic efficacy of the encapsulated drug (Youan et 
al., 2001). The absorbance measurement of cefotaxime 
standard solution containing 20 to 100 mcg/ml of drug in 
pH 7.4 PBS as shown in Figure 1 presented the standard 
calibration curve. The curve was found to be linear in the 
range of 20 to 100 mcg/ml at λmax 256 nm. The 
regression coefficient value was found to be 0.9887. 




Table 3. Encapsulation efficiency of cefotaxime. 
 
Sample No. 
Absorbance of drug 
loaded (O.D.) 
Absorbance of 
free drug (O.D.) 
Encapsulation 
efficiency (%) 
Mean (±) *STDEV **STDREV 
Cef-NP1 3.097 3 74.57 3.0485 0.068589 0.0485 
Cef-NP2 3.019 2.987 90.77 3.003 0.022627 0.016 
Cef-NP3 3.126 2.969 58.84 3.0475 0.111016 0.0785 
Cef-NP4 3.098 2.965 61.65 3.0315 0.094045 0.0665 
 










Optimization of polymer and emulsifier ratio 
 
For enhanced drug encapsulation, the results of this 
study showed that the drug/polymer and surfactant ratios 
and the concentration values influenced the final 
properties of the prepared nanoparticles. For PVA-
emulsified PCL nanoparticle formation, drug concentration 
was kept constant at 5 mg per formulation, and PCL 
concentration varied from 1 to 2 g to give a drug/polymer 
ratio of 1:10 and 1:20. And for PVA concentration, it was 
from 1:1 and 1:2. These two different ratios of PCL and 
poly vinyl alcohol were applied. In this way, four 
formulations were prepared. The percentage of nano-
particles yields varied from 55 to 54 mg corresponding to 
the amount of total amount of ingredients from 57 to 98 
mg shown in Table 2. The results showed that the 
percentage of practical yield increased as the amount of 
polymer added to each formulation increased, although it 
may not be dependent upon PVA concentration in the 
formulation. Maximum yield was found to be 75 % for 
Cef-NP2 and 78.9% for Cef-NP3. 
 
 
Drug encapsulation efficiency  
 
The drug content in four batches of Cefo-NPs was 
studied. Table 3 and Figure 2 show the results of the 
drug encapsulation efficiency in each of these 
formulations. It was observed that the encapsulation 
efficiency increases with the increase in concentration of 
polymer in the formulations. The maximum encapsulation 
was 90.77 and 74.57% found in Cef-NP2 and Cef-NP1, 
respectively. Furthermore, the encapsulation efficiency 
increases as PVA concentration also increases on 
increasing the concentration of internal phase as 
indicated in Table 3 and drug content in Figure 2.  
In this study, the result shows that encapsulation 
efficiency of the drug was depended on the solubility of 
the drug in the solvent and continuous phase. A similar 
observation was reported by Pignatello et al. (1997). The 
reason could be due to increase in size to encapsulate 
more drug and more surfactant similarly speed up the 
encapsulation process by enhancing the binding contact 
between drug and polymer in emulsion stage. 
They are two important factors effect on the 
encapsulation efficiency, the type of polymer with the 
concentration and organic solvent selection. Large size 
nanoparticles are produced whenever high concentration 
of polymer in organic phase is applied (Dey et al., 2009). 
An interesting study found out that the stability of the 
emulsion droplets has an effect on the size of the 
formulated nanoparticles which is affected by miscibility 
of organic phase with water (Lourenço and Pinto, 2009). 
In this study, using dichloromethane as a water immiscible 





Table 4. Size distribution of nanoparticles formulation 
with zeta potential. 
 
Nanoformulation Particle size (nm) Zeta potential (mV) 
Cefo-NP1 204 -45  (±) 0.78 
Cefo-NP2 219 -58  (±) 1.2 
Cefo-NP3 209 -34  (±) 3.1 




emulsification mechanism in which the larger emulsion 
droplets are broken into smaller droplets by the 
application of external energy.  
 
 
Particle size and Zeta potential 
 
The particle size of all formulated nanoparticles was 
estimated and was found to be in the range of 180 to 220 
nm which indicates that they are stable. As the 
concentration of polymer increased, the particle size also 
increased. Furthermore, when the concentration of 
stabilizer (PVA) was increased, there was a decrease in 
the particle size from 219 to 189 nm. The polymer 
concentration in the internal phase is a crucial factor in 
increasing the size of nanoparticles. It was found out that 
high viscosity of the dispersion leads to higher resistance 
shear forces of emulsification. Therefore, at high viscous 
dispersions, the globule size of emulsions obtained will 
be higher, resultantly; after evaporation of solvent, higher 
size of nanoparticles were obtained. Earlier studies found 
out that particle size was proportional to the viscosity of 
the dispersed phase (Kim et al., 2002; Si and Samulski, 
2008).  
The stability study of the nanoformulation was 
performed by measuring the zeta potential of the 
nanoparticles using the zeta meter ± 3M. The results are 
evaluated in Table 4. 
The significance value of using zeta potential is that its 
value can be related to the stability of colloidal dispersion. 
The zeta potential indicates the degree of repulsion bet-
ween adjacent, similarly charged particles in dispersion. 
For molecules and particles that are small enough, a high 
zeta potential will confer stability, that is, the solution or 




Fourier transform infrared spectroscopy (FTIR) 
 
Preformulation studies were carried out to study the 
compatibility of cefotaxime with PCL prior to the 
preparation of cefotaxime loaded nanoparticles. Infrared 
spectra of pure cefotaxime and PCL and their combination 
were studied. The FTIR studies show that there was no 
interaction between the drug and the polymer used. As 
indicated in the Figure 4. FTIR spectra of cefotaxime and 
its  complex  are  similar  and  the  main  frequencies  are  




shown in Figures 3 and 4. The lactam (C=O) band 
appears at 1780 cm
-1
 in the spectrum of cefotaxime, 
while the overlapped amide and ester (C=O) bands 
appear at 1640 cm
-1
; the complexes show these bands at 
around 1720 to 1740 and 1630 to 1650 cm
-1
 ranges, 
respectively. All this suggests that coordination of the 
ligand occurs through the oxygen atom from the lactam 
carbonyl group rather than the amide and ester carbonyl 
groups. The lactam carbonyl bands were substantially 
shifted toward lower frequencies (40 to 60 cm
-1
) relative 
to the value of the uncomplexed cefotaxime, while in the 
overlapped amide and ester carbonyl bands, the shifting 
was not significant (Chernysheva et al., 2003). 
 
 
Atomic force microscopy (AFM) of Cefo-NPs 
 
The AFM images showed that the nanoparticles formed 
as a result of solvent evaporation were spherical shaped 
and smooth in surface morphology, with an average 
diameter of less than 200 nm (Figure 5).The topography 
of cefotaxime nanoparticles were observed using AFM 
and it was found that the average diameter for Cef-NP1 
was 109.8 nm, while it was 90.7 nm for Cef-NP2 
formulation. In addition, the AFM of Cef-NP3 and Cef-
NP4 nanoparticles were 103.9 and 74 nm (cumulative 
data details not published), respectively. Results showed 
no significant adsorption at the organic/aqueous phase 
boundary when DCM was applied as organic solvent. 
And thus, resulting in higher interfacial tension, causing 
agglomeration to occur, and hence the bigger particle 
sizes (Chernysheva et al., 2003). All the nanoparticles 
prepared with DCM as solvents were not uniform. 
Sample preparation plays an important factor in order 
to get useful AFM images (Song et al., 2006). Samples 
must be thin enough and must adhere well to the surface, 
otherwise, the scanning process will producing artefacts. 
More details are presented in Chicea et al. (2012). In 
order to prepare the sample, a drop of nanofluid was 
deposited on a freshly cleaved mica substrate and 
stretched with a blade to form a very thin layer. The thin 
layer was left for 3 h to evaporate. The sample was 
attached to the AFM plate. First, a large area (5 μm × 5 
μm) surface scan was carried out. Since the resolution 
used in the first scan is not good enough to image 
nanoparticles on a surface, several scans were done to 
select a flat area on the surface where there appear to be 
singular nanoparticles rather than aggregates, which 
were present, as well. Finally, a bigger resolution scan 
(512×512 pixels) was achieved and the topography is as 
shown in Figure 5. The scanned area is 1.0 μm × 1.0, 
several aggregates nanoparticles located on the scanned 
area is noticed. 
 
 
In vitro drug release of Cefo-NPs 
 
In vitro release profile of formulations is as shown in 
Figure 6. All the selected formulations showed  sustained 






Figure 3. Zeta potential distribution curve of four formulated nanoparticles: (A) Cefo-NP1, (B) Cefo-NP2, (C) Cefo-NP3, and (D) Cefo-NP4. 






Figure 4. FTIR spectra of cefotaxime nanoparticle (NP-Cefo), Cefotaxime, Polycaprolactone-poly vinyl alcohol (PCL-PVA), 





















release patterns of drug in just 2 h. Except Cef-
NP1 showed controlled release up to 8 h. Cef-
NP4 formulation showed 95.37% release after 6 
h.  Whereas  CCef-NP2   batch   showed   94.29% 
release in 12 h. From the results of data fitting to 
various models, Cef-NP4 formulation shows 
controlled release. Cefotaxime was abruptly 
released  from  Cef-NPs  under  acidic   conditions 
(pH 1.5) with about 60% of drug release within 6 
h. Whereas only 30% was released at lower pH 
conditions (pH 1.5 and 4.5) during the same time 
period and both release profiles showed sustained  
 
    
 










































































release patterns for 96 h. 
pH-sensitive nanoparticles represented as un-
conventional disperse systems for the nanometer size. 
Regarding to their effect in protecting the macromolecules 
from the acidity of stomach, clearance metabolism in the 
gastrointestinal tract reduce the drug side effect 
(Magenheim and Benita, 1991; Kreuter et al., 1989; 
McClean et al., 1998). Furthermore, due to their inherent 
pH sensitive property, the immerse drug will be able to 
release a specific pH within the gastrointestinal tract, next 
to its target window (Dai et al., 2004; Pereira et al., 2010). 
This system showed promising results to overcome many 
problems in relation to poor permeability of certain 
compounds and improve their oral bioavailability (Li et al., 
2014). 
In the present study, an attempt was made to develop 
Cefo-NPs for controlled release, improved drug efficacy, 
reducing drug toxicity and prolong the half lives in blood. 
And it was found out that these nanoparticles were 
successfully prepared by using oil/water solvent 
evaporation method. PCL is a suitable carrier for 
preparing nanoparticles of cefotaxime, as well as, solvent 
evaporation method has the advantages of being simple, 
fast and suitable for commercial scale up of 
nanoparticles. PVA seems to be the compatible stabilizer 
with clarithromycin. The presence of PVA stabilizes the 
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